본문 바로가기
KERD
논문KCI 등재

Potential Candidates for Biomarkers in Bipolar Disorder: A Proteomic Approach through Systems Biology

Paola Rampelotto Ziani|Jacson Gabriel Feiten|Jéferson Ferraz Goularte|Rafael Colombo|Bárbara Antqueviezc|Luiza Paul Géa|Adriane Ribeiro Rosa
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2022.05|Clinical Psychopharmacology and Neuroscience|제20권 제2호|pp. 211-227|DOI 10.9758/cpn.2022.20.2.211

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Bipolar disorderBloodBiomarkersProteomicsSystems biology.

초록

Bipolar disorder (BD) is one of the most disabling diseases characterized by severe humor fluctuation. It is accompanied by cognitive and functional impairment in addiction to high suicide rates. BD is often underdiagnosed and treated incorrectly because many of the reported symptoms are not exclusive to the disorder. Once the diagnosis is exclusively clinical, it is not possible to state precisely. From that, proteomic approaches were used to identify, in a large scale, all proteins involved in cellular or tissue processes. This review aggregate data from blood proteomes, by using protein association network, of subjects with BD and healthy controls to suggest dysfunctional molecular pathways involved in disease. Original articles containing proteomic analysis were searched in PubMed. Seven studies were selected and data were extracted for posterior analysis. A protein-protein interaction network was created by STRING database. A final set of proteins in this network were employed as input in ClueGO and, the main biological process was visualized using R package pathview. The analysis revealed proteins associated with many biological processes, including growth and endocrine regulation, iron transportation, protease inhibition, protection against pathogens and cholesterol transport. Moreover, pathway analysis indicated the association of uncovered proteins with two main metabolic pathways: complement system and coagulation cascade. Thus, a better understanding on the pathophysiology of psychiatric disorders and the identification of potential biomarker candidates are essential to improve diagnostic, prognostic and design pharmacological strategies.

Abstract

Bipolar disorder (BD) is one of the most disabling diseases characterized by severe humor fluctuation. It is accompanied by cognitive and functional impairment in addiction to high suicide rates. BD is often underdiagnosed and treated incorrectly because many of the reported symptoms are not exclusive to the disorder. Once the diagnosis is exclusively clinical, it is not possible to state precisely. From that, proteomic approaches were used to identify, in a large scale, all proteins involved in cellular or tissue processes. This review aggregate data from blood proteomes, by using protein association network, of subjects with BD and healthy controls to suggest dysfunctional molecular pathways involved in disease. Original articles containing proteomic analysis were searched in PubMed. Seven studies were selected and data were extracted for posterior analysis. A protein-protein interaction network was created by STRING database. A final set of proteins in this network were employed as input in ClueGO and, the main biological process was visualized using R package pathview. The analysis revealed proteins associated with many biological processes, including growth and endocrine regulation, iron transportation, protease inhibition, protection against pathogens and cholesterol transport. Moreover, pathway analysis indicated the association of uncovered proteins with two main metabolic pathways: complement system and coagulation cascade. Thus, a better understanding on the pathophysiology of psychiatric disorders and the identification of potential biomarker candidates are essential to improve diagnostic, prognostic and design pharmacological strategies.

참고문헌 (123)

  1. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
  2. Rosa AR, "Clinical staging in bipolar disorder : focus on cognition and functioning", J Clin Psychiatry, 75, pp.e450~e456 (2014)
  3. "Bipolar disorder"[URL]
  4. Crump C, "Comorbidities and mortality in bipolar disorder : a Swedish national cohort study", JAMA Psychiatry, 70, pp.931~939 (2013)
  5. Grande I, "Bipolar disorder", Lancet, 387, pp.1561~1572 (2016)
  6. Gitlin MJ, "Relapse and impairment in bipolar disorder", Am J Psychiatry, 152, pp.1635~1640 (1995)
  7. World Health Organization, "International statistical classification of diseases and related health problems" (2016), World Health Organization
  8. Scifo E, "Sustained molecular pathology across episodes and remission in major depressive disorder", Biol Psychiatry, 83, pp.81~89 (2018)
  9. Vieta E, "Functional remediation : the pathway from remission to recovery in bipolar disorder", World Psychiatry, 15, pp.288~289 (2016)
  10. Chen J, "Comparative proteomic analysis of plasma from bipolar depression and depressive disorder : identification of proteins associated with immune regulatory", Protein Cell, 6, pp.908~911 (2015)
  11. Stern S, "Prediction of response to drug therapy in psychiatric disorders", Open Biol, 8, pp.180031~ (2018)
  12. Frey BN, "Biomarkers in bipolar disorder : a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force", Aust N Z J Psychiatry, 47, pp.321~332 (2013)
  13. Song YR, "Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorder", Braz J Med Biol Res, 48, pp.973~982 (2015)
  14. Saia-Cereda VM, "Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients", Schizophr Res, 177, pp.70~77 (2016)
  15. Bayés A, "Characterization of the proteome, diseases and evolution of the human postsynaptic density", Nat Neurosci, 14, pp.19~21 (2011)
  16. Alsaif M, "Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection", Proteomics Clin Appl, 6, pp.297~303 (2012)
  17. de Jesus JR, "Simplifying the human serum proteome for discriminating patients with bipolar disorder of other psychiatry conditions", Clin Biochem, 50, pp.1118~1125 (2017)
  18. Haenisch F, "Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3β signaling in bipolar patients", J Affect Disord, 156, pp.139~143 (2014)
  19. Herberth M, "Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival", Proteomics, 11, pp.94~105 (2011)
  20. Ren J, "Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS", MS and bioinformatics analysis, 2017, pp.86, 17~24
  21. Szklarczyk D, "STRING v11 : protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets", Nucleic Acids Res, 47(D1), pp.D607~D613 (2019)
  22. Bindea G, "ClueGO : a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks", Bioinformatics, 25, pp.1091~1093 (2009)
  23. Shannon P, "Cytoscape : a software environment for integrated models of biomolecular interaction networks", Genome Res, 13, pp.2498~2504 (2003)
  24. Luo W, "Pathview : an R", Bioconductor package for pathway-based data integration and visualization, 2013, pp.29, 1830~1831
  25. Hajishengallis G, "Novel mechanisms and functions of complement", Nat Immunol, 18, pp.1288~1298 (2017)
  26. Alper CA, "Studies of hepatic synthesis in vivo of plasma proteins, including orosomucoid, transferrin, alpha 1-antitrypsin, C8, and factor B", Clin Immunol Immunopathol, 16, pp.84~89 (1980)
  27. Gabrielsson BG, "High expression of complement components in omental adipose tissue in obese men", Obes Res, 11, pp.699~708 (2003)
  28. Sekar A, "Schizophrenia risk from complex variation of complement component 4", Nature, 530, pp.177~183 (2016)
  29. Ricklin D, "Complement : a key system for immune surveillance and homeostasis", Nat Immunol, 11, pp.785~797 (2010)
  30. Yang X, "Increased serum C3 and decreased UA in patients of bipolar disorder in Chinese Han population", Front Psychiatry, 9, pp.381~ (2018)
  31. Akcan U, "Bipolar disorder patients display reduced serum complement levels and elevated peripheral blood complement expression levels", Acta Neuropsychiatr, 30, pp.70~78 (2018)
  32. Reginia A, "Assessment of complement cascade components in patients with bipolar disorder", Front Psychiatry, 9, pp.614~ (2018)
  33. Coulthard LG, "Complement : the emerging architect of the developing brain", Trends Neurosci, 41, pp.373~384 (2018)
  34. Hong S, "New insights on the role of microglia in synaptic pruning in health and disease", Curr Opin Neurobiol, 36, pp.128~134 (2016)
  35. Oda MN, "Lipid-free apoA-I structure-origins of model diversity", Biochim Biophys Acta Mol Cell Biol Lipids, 1862, pp.221~233 (2017)
  36. Arciello A, "Apolipoprotein A-I : the dual face of a protein", FEBS Lett, 590, pp.4171~4179 (2016)
  37. Rachmilewitz D, "Apolipoprotein A-I synthesis and secretion by cultured human intestinal mucosa", Metabolism, 28, pp.739~743 (1979)
  38. Chisholm JW, "ApoA-I secretion from HepG2 cells : evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL", J Lipid Res, 43, pp.36~44 (2002)
  39. Huang JT, "Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues", Mol Psychiatry, 13, pp.1118~1128 (2008)
  40. Ezzaher A, "Thyroid function and lipid profile in bipolar I patients", Asian J Psychiatr, 4, pp.139~143 (2011)
  41. Xu YY, "Factors related to lithium blood concentrations in Chinese Han patients with bipolar disorder", Neuropsychiatr Dis Treat, 15, pp.1929~1937 (2019)
  42. Schwarz E, "Identification of a biological signature for schizophrenia in serum", Mol Psychiatry, 17, pp.494~502 (2012)
  43. Murphy AJ, "High-density lipoprotein reduces the human monocyte inflammatory response", Arterioscler Thromb Vasc Biol, 28, pp.2071~2077 (2008)
  44. Iqbal AJ, "Acute exposure to apolipoprotein A1 inhibits macrophage chemotaxis in vitro and monocyte recruitment in vivo", Elife, 5, pp.e15190~ (2016)
  45. Pamela Ferrari, "Depression and Mania Induce Pro-inflammatory Activation of Macrophages Following Application of Serum from Individuals with Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 16(1), pp.103~108 (2018), 대한정신약물학회[DOI]
  46. Ascoli BM, "Attenuated inflammatory response of monocyte-derived macrophage from patients with BD : a preliminary report", Int J Bipolar Disord, 7, pp.13~ (2019)
  47. Brietzke E, "Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder", J Affect Disord, 116, pp.214~217 (2009)
  48. Rosenblat JD, "Bipolar disorder and inflammation", Psychiatr Clin North Am, 39, pp.125~137 (2016)
  49. Munkholm K, "Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis", J Psychiatr Res, 47, pp.1119~1133 (2013)
  50. Chifman J, "A systems biology approach to blood", pp.201~225 (2014), Springer
  51. Gomme PT, "Transferrin : structure, function and potential therapeutic actions", Drug Discov Today, 10, pp.267~273 (2005)
  52. Murakami Y, "Transferrin isoforms in cerebrospinal fluid and their relation to neurological diseases", Proc Jpn Acad Ser B Phys Biol Sci, 95, pp.198~210 (2019)
  53. Stelzhammer V, "Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients", Int J Neuropsychopharmacol, 17, pp.1599~1608 (2014)
  54. Maes M, "Interleukin-2 and interleukin-6 in schizophrenia and mania : effects of neuroleptics and mood stabilizers", J Psychiatr Res, 29, pp.141~152 (1995)
  55. Tsai SY, "Plasma levels of soluble transferrin receptors and Clara cell protein(CC16)during bipolar mania and subsequent remission", J Psychiatr Res, 37, pp.229~235 (2003)
  56. Geiser F, "Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants", Psychiatry Clin Neurosci, 65, pp.518~525 (2011)
  57. Musselman DL, "Exaggerated platelet reactivity in major depression", Am J Psychiatry, 153, pp.1313~1317 (1996)
  58. Tang X, "Transferrin plays a central role in coagulation balance by interacting with clotting factors", Cell Res, 30, pp.119~132 (2020)
  59. Stack AG, "Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population", QJM, 107, pp.623~633 (2014)
  60. Ahmed MS, "Acute phase reactants as novel predictors of cardiovascular disease", ISRN Inflamm, 2012, pp.953461~ (2012)
  61. De Luca C, "Neuro-immune hemostasis : homeostasis and diseases in the central nervous system", Front Cell Neurosci, 12, pp.459~ (2018)
  62. Lang UE, "Molecular mechanisms of depression : perspectives on new treatment strategies", Cell Physiol Biochem, 31, pp.761~777 (2013)
  63. Hoirisch-Clapauch S, "Coagulation and mental disorders", Rambam Maimonides Med J, 5, pp.e0036~ (2014)
  64. Oliveira CRP, "Papel emergente do eixo GH", IGF-I no controle cardiometabólico, 2011, pp.97, 434~439
  65. Boguszewski CL, "Genética molecular do eixo GH-IGF1", Arq Bras Endocrinol Metab, 45, pp.5~14 (2001)
  66. Frysak Z, "Insulin-like growth factors in a clinical setting : review of IGF-I", Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 159, pp.347~351 (2015)
  67. Di Bona D, "Association between genetic variations in the insulin", insulin-like growth factor(Igf-1)signaling pathway and longevity : a systematic review and meta-analysis, 2014, pp.12, 674~681
  68. insulin receptor binding sites in developing and adult rat brain, "J Comp Neurol", 1993, 375~397
  69. Man HY, "Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization", Neuron, 25, pp.649~662 (2000)
  70. Nuñez A, "Insulin-like growth factor I modifies electrophysiological properties of rat brain stem neurons", J Neurophysiol, 89, pp.3008~3017 (2003)
  71. Lupien SB, "Systemic insulin-like growth factor-I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning", memory in normal adult rats, 2003, pp.74, 512~523
  72. Bluthé RM, "Effects of insulin-like growth factor-I on cytokine-induced sickness behavior in mice", Brain Behav Immun, 20, pp.57~63 (2006)
  73. Kim YK, "High insulin-like growth factor-1 in patients with bipolar I disorder : a trait marker?", J Affect Disord, 151, pp.738~743 (2013)
  74. Milanesi E, "Insulin-like growth factor 1 differentially affects lithium sensitivity of lymphoblastoid cell lines from lithium responder and non-responder bipolar disorder patients", J Mol Neurosci, 56, pp.681~687 (2015)
  75. da Silva EG, "Peripheral insulin-like growth factor 1 in bipolar disorder", Psychiatry Res, 250, pp.30~34 (2017)
  76. Tu KY, "Significantly higher peripheral insulin-like growth factor-1levels in patients with major depressive disorder or bipolar disorder than in healthy controls: a meta-analysis and review under guideline of PRISMA", Medicine(Baltimore), 95, pp.e2411~ (2016)
  77. Spielman LJ, "Inflammation and insulin", IGF-1 resistance as the possible link between obesity and neurodegeneration, 2014, pp.273, 8~21
  78. Lontchi-Yimagou E, "Diabetes mellitus and inflammation", Curr Diab Rep, 13, pp.435~444 (2013)
  79. Labandeira-Garcia JL, "Insulin-like growth factor-1 and neuroinflammation", Front Aging Neurosci, 9, pp.365~ (2017)
  80. Park SE, "Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice", J Neuroinflammation, 8, pp.12~ (2011)
  81. Rehman AA, "α-2-macroglobulin : a physiological guardian", J Cell Physiol, 228, pp.1665~1675 (2013)
  82. Cater JH, "Alpha-2-macroglobulin, a hypochlorite-regulated chaperone and immune system modulator", Oxid Med Cell Longev, 2019, pp.5410657~ (2019)
  83. Varma VR, "Alpha-2 macroglobulin in Alzheimer’s disease : a marker of neuronal injury through the RCAN1 pathway", Mol Psychiatry, 22, pp.13~23 (2017)
  84. Gupta AK, "Cerebrospinal fluid proteomics for identification of α2-macroglobulin as a potential biomarker to monitor pharmacological therapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia", Neuropsychiatr Dis Treat, 15, pp.2853~2867 (2019)
  85. Cattaneo A, "FoxO1, A2M, and TGF-β1 : three novel genes predicting depression in gene X environment interactions are identified using cross-species and cross-tissues transcriptomic and miRNomic analyses", Mol Psychiatry, 23, pp.2192~2208 (2018)
  86. Fujita T, "Circulating alpha-2-macroglobulin levels and depression scores in patients who underwent abdominal cancer surgery", J Surg Res, 114, pp.90~94 (2003)
  87. Seidel A, "Cytokine production and serum proteins in depression", Scand J Immunol, 41, pp.534~538 (1995)
  88. Rothermundt M, "Inflammatory markers in major depression and melancholia", J Affect Disord, 63, pp.93~102 (2001)
  89. Yee JY, "Peripheral blood gene expression of acute phase proteins in people with first episode psychosis", Brain Behav Immun, 65, pp.337~341 (2017)
  90. Felger JC, "Imaging the role of inflammation in mood and anxiety-related disorders", Curr Neuropharmacol, 16, pp.533~558 (2018)
  91. Maes M, "Acute phase proteins in schizophrenia, mania and major depression : modulation by psychotropic drugs", Psychiatry Res, 66, pp.1~11 (1997)
  92. Krem MM, "Evolution of enzyme cascades from embryonic development to blood coagulation", Trends Biochem Sci, 27, pp.67~74 (2002)
  93. Oncul S, "The interaction between the complement system and hemostatic factors", Curr Opin Hematol, 27, pp.341~352 (2020)
  94. Luo S, "Complement in hemolysis-and thrombosis-related diseases", Front Immunol, 11, pp.1212~ (2020)
  95. Luyendyk JP, "The multifaceted role of fibrinogen in tissue injury and inflammation", Blood, 133, pp.511~520 (2019)
  96. Chaudhry R, "Physiology, coagulation pathways" (2020), StatPearls
  97. Rogers HJ, "Hematopathology", pp.57~105 (2018), Elsevier
  98. Esmon CT, "The impact of the inflammatory response on coagulation", Thromb Res, 114, pp.321~327 (2004)
  99. Fletcher-Sandersjöö A, "Does complement-mediated hemostatic disturbance occur in traumatic brain injury? A literature review and observational study protocol", Int J Mol Sci, 21, pp.1596~ (2020)
  100. Dietrich-Muszalska A, "Platelet haemostatic function in psychiatric disorders : effects of antidepressants and antipsychotic drugs", World J Biol Psychiatry, 18, pp.564~574 (2017)
  101. Kattula S, "Fibrinogen and fibrin in hemostasis and thrombosis", Arterioscler Thromb Vasc Biol, 37, pp.e13~e21 (2017)
  102. Eriksson O, "The human platelet as an innate immune cell : interactions between activated platelets and the complement system", Front Immunol, 10, pp.1590~ (2019)
  103. Tarandovskiy ID, "Contradictory to its effects on thrombin, C1-inhibitor reduces plasmin generation in the presence of thrombomodulin", J Thromb Thrombolysis, 48, pp.81~87 (2019)
  104. Chapin J, "The role of complement activation in thrombosis and hemolytic anemias", Transfus Apher Sci, 54, pp.191~198 (2016)
  105. Lupu F, "Crosstalk between the coagulation and complement systems in sepsis", Thromb Res, 133(Suppl 1), pp.S28~S31 (2014)
  106. Wadee AA, "Serological observations in patients suffering from acute manic episodes", Hum Psychopharmacol, 17, pp.175~179 (2002)
  107. Bester J, "Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity", Sci Rep, 6, pp.32188~ (2016)
  108. Yan SL, "Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6", Inflamm Bowel Dis, 20, pp.353~362 (2014)
  109. Kapczinski F, "A systemic toxicity index developed to assess peripheral changes in mood episodes", Mol Psychiatry, 15, pp.784~786 (2010)
  110. Lendak D, "Complement component consumption in sepsis correlates better with hemostatic system parameters than with inflammatory biomarkers", Thromb Res, 170, pp.126~132 (2018)
  111. Mazza MG, "Cross-sectional study of neutrophil-lymphocyte, plateletlymphocyte and monocyte-lymphocyte ratios in mood disorders", Gen Hosp Psychiatry, 58, pp.7~12 (2019)
  112. Paradise HT, "Outcomes of anticoagulation therapy in patients with mental health conditions", J Gen Intern Med, 29, pp.855~561 (2014)
  113. Razouki Z, "Pathways to poor anticoagulation control", J Thromb Haemost, 12, pp.628~634 (2014)
  114. Greenberg ME, "New insights in the biology of BDNF synthesis and release : implications in CNS function", J Neurosci, 29, pp.12764~12767 (2009)
  115. Autry AE, "Brain-derived neurotrophic factor and neuropsychiatric disorders", Pharmacol Rev, 64, pp.238~258 (2012)
  116. Chiou YJ, "Brain-derived neurotrophic factor(BDNF)and bipolar disorder", Psychiatry Res, 274, pp.395~399 (2019)
  117. Jiang H, "The serum protein levels of the tPA-BDNF pathway are implicated in depression and antidepressant treatment", Transl Psychiatry, 7, pp.e1079~ (2017)
  118. Rowland T, "Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder : systematic review and meta-analyses", Br J Psychiatry, 213, pp.514~525 (2018)
  119. Chen S, "Combined serum levels of multiple proteins in tPA-BDNF pathway may aid the diagnosis of five mental disorders", Sci Rep, 7, pp.6871~ (2017)
  120. Martins-de-Souza D, "Proteomic technologies for biomarker studies in psychiatry : advances and needs", Int Rev Neurobiol, 101, pp.65~94 (2011)
  121. Roda Â, "Biomarkers and staging of bipolar disorder : a systematic review", Trends Psychiatry Psychother, 37, pp.3~11 (2015)
  122. Cipriani A, "valproate and divalproex in the maintenance treatment of bipolar disorder", Cochrane Database Syst Rev, 2013, pp.CD003196~ (2013)
  123. Morsel AM, "An overview of pharmacotherapy for bipolar I disorder", Expert Opin Pharmacother, 19, pp.203~222 (2018)

관련 논문AI추천

Are Mannan-binding Lectine Serin Protease-2 and Alpha-1-microglobulin and Bukinin Precursor the Potential Biomarkers of Manic Episode? A Study via Urinary Proetomic AnalysisCem Cerit, Gürler Akpınar, Hilmi Yaşar, Mehmet Sarıhan, Murat Kasap, Ömer Nart대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제2호Bipolar Disorder: Role of Inflammation and the Development of Disease BiomarkersAther Muneer대한신경정신의학회 · PSYCHIATRY INVESTIGATION2016 · 제13권 제1호주요우울장애의 병태생리 해석을 위한 혈청 단백체 기반 네트워크 분석KANG Hee-Gyoo, LEE Seungyeon대한임상검사과학회 · 대한임상검사과학회지2025 · 제57권 제3호Proteomics as a Tool for Understanding SchizophreniaDaniel Martins-de-Souza대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2011 · 제9권 제3호Multiple Complement Pathway-related Proteins Might Regulate Immunopathogenesis of Major Depressive DisorderGanesan Venkatasubramanian, Kesavan Muralidharan, Manjula Subbanna, Monojit Debnath, Pinku Mani Talukdar, Praerna H. Bhargav, Preethi V. Reddy, Rashmi Arasappa대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2023 · 제21권 제2호Biomarkers of Major Depressive Disorder: Knowing is Half the BattleAkriti Dangol, Govind Arora, Ravinder Singh, Sahil Malik, Sanjay Goyal대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제1호

이 간행물의 다른 논문 (20건)

Proposed Pathway Linking Respiratory Infections with DepressionNajmeh Parhizgari, Zeinab Karimi, Maryam Chenari, Farhad Rezaie, Shima Karimi, Talat Mokhtari-Azadpp. 199-210Neuromolecular Etiology of Bipolar Disorder: Possible Therapeutic Targets of Mood Stabilizers박성우, 박원명, Dae-Hyun Seog, 이정구, Young Sup Woo, Mi Kyoung Seopp. 228-239The Evaluation of Thiol/Disulfide Homeostasis and Oxidative DNA Damage in Patients with Obsessive Compulsive DisorderYavuz Selim Atan, Mesut Işık, Hamit Hakan Alp, Faruk Kurhanpp. 240-247Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive DisordersRobert Stewart, Hee Kyung Kim, Ho-Cheol Kang, 강희주, Sung-Wan Kim, Jae-Min Kim, Ju-Wan Kim, Ju-Yeon Lee, Wonsuk Choipp. 248-258Effects of Methylphenidate on Somatic Symptoms and Brain Functional Connectivity in Adolescents with Attention Deficit Hyperactivity Disorder: A Pilot StudyDoug Hyun Han, 김선미, Kyung Joon Minpp. 259-270
원문 보기